|
2. Etiologie
|
|
|
Vitamins and Cancer Risk [Science-Based Medicine]
|
|
|
|
|
|
It’s
quite possible that vitamin supplement use, in addition to costing
billions of dollar per year, has been a net health negative. We can save
money and ensure that it is a net health positive with more rational
and evidence-based supplementation.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
Safety switches may redeem potent CAR T cancer therapies [Reuters]
|
|
|
|
|
|
A third of the patients in some trials given CAR T cells have developed life-threatening fevers and inflammation. As
a result, some drugmakers are building in "switches" to suppress CAR T
cells if serious side effects emerge, or to make them self-destruct if
they attack healthy tissue.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
Company Creates Bioethics Panel on Trial Drugs [NY Times]
|
|
|
|
|
|
Officials
at Johnson & Johnson said that they had not kept track — until now —
of how many compassionate use requests the company received, but that
it probably fielded at least 100 requests a year for unapproved drugs to
treat everything from cancer to infectious diseases.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
Gilead Boosts Cancer Pipeline With $65M EpiTherapeutics Buy [GEN]
|
|
|
|
|
|
The
company’s website says its pipeline-building efforts are based
knowledge within histone demethylases and methyltransferases, as well as
“in-house drug discovery efforts to identify small molecule inhibitors
of key enzymes within the family targeting unmet medical needs.”
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Adaptimmune hauls in $191M in an upsized immuno-oncology IPO [FierceBiotech]
|
|
|
|
|
|
A
cousin to high-profile CAR-T technology, TCR therapies are designed to
train a patient's T cells to seek out specific antigens expressed by
tumors liquid and solid. Adaptimmune's lead project, partnered with
GlaxoSmithKline, targets the NY-ESO antigen and is in the midst of
clinical trials in 5 cancer varieties with more studies on the way, the
company said.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
|
How we work - Handling conflicts of interests [EMA]
|
|
|
|
|
|
The
European Medicines Agency takes care to ensure that its scientific
experts, staff and Management Board do not have any financial or other
interests that could affect their impartiality. The Agency has separate
policies in place for these groups.
|
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
|
6. Lutte contre les cancers
|
|
|
They are many, will we be too few? [Cancer World]
|
|
|
|
|
|
The
European Commission is predicting that by 2020 Europe will need an
additional one million clinical professionals to care for its ageing
population. With many of our cancer systems already working at full
capacity, this Editorial calls on the cancer community to get engaged in
discussions about the changes in working practices, training and
workforce mix that will be needed to safeguard the quality and safety of
the care we provide.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|
6.7.3 DMP
|
|
|